Advantage Alpha Capital Partners LP Reduces Position in Halozyme Therapeutics, Inc. $HALO

Advantage Alpha Capital Partners LP lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 27.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,033 shares of the biopharmaceutical company’s stock after selling 3,797 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in Halozyme Therapeutics were worth $522,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. DLD Asset Management LP purchased a new stake in shares of Halozyme Therapeutics during the second quarter valued at $650,250,000. Los Angeles Capital Management LLC lifted its holdings in Halozyme Therapeutics by 951.8% during the 2nd quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company’s stock valued at $50,650,000 after buying an additional 881,094 shares in the last quarter. Jupiter Asset Management Ltd. boosted its position in Halozyme Therapeutics by 1,012.8% in the 2nd quarter. Jupiter Asset Management Ltd. now owns 670,612 shares of the biopharmaceutical company’s stock valued at $34,885,000 after buying an additional 610,350 shares during the period. Caisse DE Depot ET Placement DU Quebec boosted its position in Halozyme Therapeutics by 154.5% in the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 910,169 shares of the biopharmaceutical company’s stock valued at $58,078,000 after buying an additional 552,590 shares during the period. Finally, Empowered Funds LLC grew its stake in Halozyme Therapeutics by 3,843.6% in the 2nd quarter. Empowered Funds LLC now owns 466,603 shares of the biopharmaceutical company’s stock worth $24,273,000 after acquiring an additional 454,771 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, October 21st. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target on the stock in a research note on Tuesday, October 14th. Morgan Stanley decreased their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a report on Monday, October 20th. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Halozyme Therapeutics in a research report on Wednesday, November 19th. Seven investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $75.10.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $72.66 on Friday. The company has a market capitalization of $8.54 billion, a PE ratio of 16.63, a P/E/G ratio of 0.35 and a beta of 1.18. The company has a 50-day simple moving average of $69.38 and a two-hundred day simple moving average of $63.72. Halozyme Therapeutics, Inc. has a one year low of $46.26 and a one year high of $79.50. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. The business had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company’s revenue was up 22.1% compared to the same quarter last year. During the same period last year, the business earned $1.27 EPS. Research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the transaction, the chief financial officer owned 24,306 shares in the company, valued at approximately $1,840,207.26. This represents a 45.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bernadette Connaughton sold 4,000 shares of the company’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total value of $294,720.00. Following the completion of the transaction, the director directly owned 46,952 shares in the company, valued at approximately $3,459,423.36. The trade was a 7.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 110,227 shares of company stock valued at $8,028,955 in the last three months. 2.40% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.